Clinical trial
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular…
NCT00400894 · ProteoSys AG, Industry · Unknown status
Key facts
| NCT number | NCT00400894 |
|---|---|
| Title | Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma |
| Official title | Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma |
| Lead sponsor | ProteoSys AG, Industry |
| Collaborators | Charite University, Berlin, Germany University Hospital Tuebingen Medical Centre, Ludwigshafen, Germany Medical University Innsbruck |
| Status | Unknown status |
| Study type | Observational |
| Conditions | Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia |
| Enrollment | 750 |
| Start date | Sep 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Nov 17, 2006 |
| Last update posted | Feb 5, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: